Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
FGI Industries (FGI)
Verdant Earth Technologies (VDNT)
Modular Medical (MODD)
Jupiter Neurosciences, Inc. (JUNS)
Sunfire Acquisition (SUNFU)
Rhodium Enterprises, Inc. (RHDM)
Four Springs Capital Trust (FSPR)
Samsara Vision (SMSA)
Priced IPO
Yoshitsu Co., Ltd. (TKLF)
Tpg Inc. (TPG)
Hillstream BioPharma (HILS)
Hour Loop (HOUR)
Vigil Neuroscience, Inc. (VIGL)
Amylyx Pharmaceuticals, Inc. (AMLX)
Cincor Pharma, Inc. (CINC)
Apptech (APCX)
NexGel, Inc. (NXGL)
Immix Biopharma (IMMX)
Bionomics Limited (BNOX)
Genenta Science (GNTA)
Samsara Inc. (IOT)
Sidus Space (SIDU)
Fresh Vine Wine, Inc. (VINE)
Nu Holdings Ltd. (NU)
Hashicorp, Inc. (HCP)
NeuroSense Therapeutics Ltd. (NRSN)
Cingulate, Inc. (CING)
Chicago Atlantic Real Estate Finance, Inc. (REFT)
More companies

Cingulate, Inc. (CING)

Sector - Healthcare

Price chart

-56.5%
Return from IPO

Company News

IPO Profile

About company

They are a clinical stage biopharmaceutical company using their proprietary Precision Timed Release, or PTR, drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. They are initially focusing their efforts on the treatment of Attention Deficit/Hyperactivity Disorder, or ADHD. Their PTR platform incorporates a proprietary Erosion Barrier Layer, or EBL, designed to allow for the release of drug substance at specific, pre-defined time intervals, unlocking the potential for once-daily, multi-dose tablets. They are initially targeting the ADHD stimulant-based treatment market, with an estimated US market size of $15.3 billion in 2020. Stimulants are the most commonly prescribed class of medications for ADHD and account for more than 90% of all ADHD medication prescriptions in the United States, where approximately 70 million stimulant prescriptions were written last year alone. By contrast, non-stimulant medications are typically employed only in the second-line or adjunctive therapy setting and account for 9-10% of all ADHD medication prescriptions.
Industry
Pharmaceutical Preparations
CEO CFO
-
Employees Founded
13 2013

Contacts

Address: 1901 W. 47th Place Kansas City, Ks 66205

Telephone: (913) 942-2300

Web page: http://www.cingulate.com

IPO information

First Trade Date 12/8/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range $10.00-$12.00
Share prices ($)

Shares & Volumes

Shares Initial (MM) 4.54
Shares Revised (MM) 4.2
Expected offer amount (MM) $39.6
Realized offer amount(MM) $25.2

Financial Data (last reporting year)

Market Cap (MM) $74.97
Revenues (MM) $0
Net Income (Loss) (MM) $-7.44

Voting

What do you think will happen with the CING share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Aegis Capital Corp.

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Aegis Capital Corp./ Laidlaw & Company (UK)
CO-Managers

Sector: Healthcare

Tweets about $CING

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats